A linear relationship between lamotrigine and GABA in cerebrospinal fluid

Yıl 2011, Cilt: 15 Sayı: 1, 1 - 6, 06.03.2014

Berna Terzioğlu Atilla Karaalp M. Gören

Öz

Kaynakça

• Bazil CW. New antiepileptic drugs. Neurology, 8:71–81, 2002.
• Kwan P, Sills GJ, Brodie MJ. The mechanism of action of com- monly used antiepileptic drugs. Pharmacol Ther, 90:21–34, 2001.
• Deckers CLP, Genton P, Sills GJ, Schmidt D. Current limita- tions of antiepileptic drug therapy: a conference review. Epi- lepsy Res, 53:1–17, 2003.
• Ferrie CD, Panayiotopoulos CP: Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure, 3:157–159, 1994.
• Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand, 91:200–202, 1995.
• Panayiotopoulos CP, CD Ferrie, C Knott, RO Robinson: Inter- action of lamotrigine with sodium valproate. Lancet, 41:445, 1993.
• Pisani F, Di Perri R, Perucca E, Richens A. Interaction of lamo- trigine with sodium valproate. Lancet, 341:1224,1993.
• Pisani F, Oteri G, Russo MF, Di Perri R, Perucca R, Richens A. The efficacy of valproatelamotrigine comedication in refacto- ry complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia, 40:1141–1146, 1999.
• Messenheimer JA. Lamotrigine. Epilepsia, 36:87–94, 1995.
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamot- rigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry, 60:79–88, 1999.
• Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al.: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipo- lar disorder. Lamictal 614 Study Group. J Clin Psychiatry, 61:841–850, 2000.
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Os- uch EA et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol, 20:607–614,2000.
• Bowden CL, Calabrese JR, Sachs GS, Yatham LN, Asghar SA, Montgomery P, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar disorder. Arch Gen Psychiatry, 60:392-400, 2003.
• Eriksson AS, O’Connor WT. Analysis of cerebrospinal fluid amino acids in young patients with generalised refractory epilepsy during an add-on study with lamotrigine. Epilepsy Res, 34:75–83, 1999.
• Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology, 58:368–372, 2002.
• Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamactil) using primary neurological cultures from rat cortex. Brain Res, 612:190–199,
• Waldmeier PC, Baumann PA, Wick P, Feldtrauer JJ, Stier- lin C, Scmutz M. Similar potency of carbamazepine, oxcar- bazepine and lamotrigine in inhibiting the release of gluta- mate and other neurotransmitters. Neurology, 45:1907–1913,
• Waldmeier PC, Martin P, Stocklin K, Portet C, Scmutz M. Ef- fect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn-Schmiedeberg’s Arch Phar- macol, 354:164–172, 1996.
• Wang SJ, Sibra TS, Gean PW. Lamotrigine inhibition of gluta- mate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. NeuroReport, 2:2255–2258, 2001.
• Cunningham MO, Jones RSG. The anticonvulsant, lamot- rigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vivo. Neuropharmacology, 39:2139–2141, 2000.
• Cunningham MO, Wood SJ, Dhillon A, Jones RSG. Reciprocal modulation of glutamate and GABA release may underlie the anticonvulsant effect of phenytoin. Neuroscience, 95:343–351, 2000.
• Braga MF, Aroniadou-Anderjaska V, Post RM, Li H. Lamo- trigine reduces spontaneous and evoked GABAA receptor- mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. Neuropharmacology, 42:522–529, 2002.
• Hassel B, Tauboll E, Gjerstad L. Chronic lamotrigine treat- ment increases rat hippocampal GABA shunt activity and el- evates cerebral taurine levels. Epilepsy Res, 43:153–163, 2001.
• Tanganelli S, Bianchi C, Beani L. The modulation of cortical acetylcholine release by GABA, GABAlike drugs and benzo- diazepines in freely moving guineapigs. Neuropharmacol- ogy, 24:291–299, 1985.
• Bianchi C, Tanganelli S, Marzola G, Beani L. GABA induced changes in acetylcholine release from slices of guinea-pig brain. Naunyn Schmiedebergs Arch Pharmacol, 318:253–258, 1982.
• McCormick DA, Prince DA. Mechanisms of action of acetyl- choline in the guinea pig cerebral cortex in vitro. J Physiol, 375:169–194, 1986.
• Raiteri M, Marchi M, Paudice P, Pittaluga A. Muscarinic re- ceptors mediating inhibition of y-aminobutyric acid release in rat corpus striatum and their pharmacological characteriza- tion. J Pharmacol Exp Ther, 254:496–501, 1990.
• Hasuo H, Gallager JP, Shinnick-Gallager P. Disinhibition in the rat septum mediated by M1 muscarinic receptors. Brain Res, 438:323-327, 1988.
• Shirakawa J, Taniyama K, lwai S, Tanaka C. Regulation [3H] GABA release from strips of guinea pig urinary bladder. Am J Physiol, 255:888-893, 1988.
• Yananli H, Gören MZ, Berkman K, Aricioğlu F. Effect of ag- matine on brain L-citrulline production during morphine withdrawal in rats: a microdialysis study in nucleus ac- cumbens. Brain Res, 1132:51-58, 2007.
• Paxinos G, Watson C. The rat brain in stereotaxic coordinates, ed 2. London Academic Press 1986.
• Yananli HR, Terzioğlu B, Goren MZ, Aker RG, Aypak C, Onat FY. Extracellular hypothalamic gamma-aminobutyric acid (GABA) and L-glutamic acid concentrations in response to bicuculline in a genetic absence epilepsy rat model. J Pharma- col Sci, 106:301-309, 2008.
• PL Wheatley, AA Miller. Effects of lamotrigine on electrically induced afterdischarge duration in anaes. thetised rat, dog, and marmoset. Epilepsia, 30:34–40, 1989.
• Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol, 46:547–551, 1998.
• Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN. Comparison of serum, cerebrospinal fluid and brain extracel- lular fluid pharmacokinetics of lamotrigine. Br J Pharmacol, 130:242–248, 2000.
• Walton NY, Jaing Q, Hyun B, Treiman DM. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res, 24:19–28, 1996.
• Parsons DN, Dickins M, Morley TJ. Lamotrigine: absorption, distribution, and excretion. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. Antiepileptic Drugs, Raven Press, New York, 1995. pp 877– 881.
• Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neu- rochemical studies on the mechanism of action. Epilepsia, 27:490–497, 1986.
• Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res, 13:107–112, 1992.
• Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther, 266:829–835, 1993.
• Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na channels and with native Na channels in rat hip- pocampal neurones. Pflugers Arch, 430:437–446, 1995.
• Lizasoain I, Knowles RG, Moncada S. Inhibition by lamot- rigine of the generation of nitric oxide in rat forebrain slices. J Neurochem, 64:636–642, 1995.
• Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol. Suppl, 1:29-37, 1997.
• Ahmad S, Fowler LJ, Whitton PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res, 1029:41-47, 2004.
• Van Der Zee EA, Luiten PGM. Cholinergic and GABAergic neurons in the rat medial septum express muscarinic acetyl- choline receptors. Brain Res, 652:263–268, 1994.
• De Boer P, Westerink BCH. GABAergic modulation of stri- atal cholinergic interneurons: An in vivo microdialysis study. J Neurochem, 62:70–75, 1994.
• Tellioglu T, Akin S, Ozkutlu U, Oktay S, Onat F. The role of brain acetylcholine in GABAA receptor antagonist-induced blood-pressure changes in rat. Eur J Pharmacol, 317:301-307,
• Onat F, Tellioglu T, Aker R, Goren Z, Iskender E, Oktay S. Ef- fect of muscimol on cholinomimetic-induced cardiovascular responses in rats. Eur J Pharmacol, 362:173-181, 1988.
• Kayadjanian N, Menetrey A, Besson MJ. Activation of mus- carinic receptors stimulates GABA release in the rat globus pallidus. Synapse, 26:131–139, 1997.
• Baba H, Kohno H, Okamoto M, Goldstein PA, Shimoji K, Yoshimura M. Muscarinic facilitation of GABA release in substantia gelatinosa of the rat spinal dorsal horn. J Physiol, 508:83-93, 1998.
• Grillner P, Berretta N, Bernardi G, Svensson TH, Mercuri NB. Muscarinic receptors depress GABAergic synaptic trans- mission in rat midbrain dopamine neurons. Neuroscience, 96:299–307, 2000.